Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondylitis switching anti tumor necrosis factor α therapy: Results from the Danish nationwide Danbio registry

Bente Glintborg; Mikkel Østergaard; N. Krogh; U. Tarp; A. Loft; Annette Hansen; Annette Schlemmer; V. Fana; M. Kristensen; Hanne Merete Lindegaard; H. Nordin; C. Rasmussen; L. Ejstrup; P.M. Petersen; N. Manilo; Dorte Vendelbo Jensen; Merete Lund Hetland

Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondylitis switching anti tumor necrosis factor α therapy: Results from the Danish nationwide Danbio registry

Bente Glintborg, Mikkel Østergaard, N. Krogh, U. Tarp, A. Loft, Annette Hansen, Annette Schlemmer, V. Fana, M. Kristensen, Hanne Merete Lindegaard, H. Nordin, C. Rasmussen, L. Ejstrup, P.M. Petersen, N. Manilo, Dorte Vendelbo Jensen, Merete Lund Hetland

Department for Rheumatology and Spine Diseases

Original language	English
Journal	Annals of the Rheumatic Diseases
Volume	71
Issue number	Suppl. 3
Pages (from-to)	111
Number of pages	1
ISSN	0003-4967
Publication status	Published - 2012

Cite this

Glintborg, B., Østergaard, M., Krogh, N., Tarp, U., Loft, A., Hansen, A., Schlemmer, A., Fana, V., Kristensen, M., Lindegaard, H. M., Nordin, H., Rasmussen, C., Ejstrup, L., Petersen, P. M., Manilo, N., Jensen, D. V., & Hetland, M. L. (2012). Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondylitis switching anti tumor necrosis factor α therapy: Results from the Danish nationwide Danbio registry. Annals of the Rheumatic Diseases, 71(Suppl. 3), 111.

Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondylitis switching anti tumor necrosis factor α therapy: Results from the Danish nationwide Danbio registry. / Glintborg, Bente ; Østergaard, Mikkel; Krogh, N. et al.
In: Annals of the Rheumatic Diseases, Vol. 71, No. Suppl. 3, 2012, p. 111.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Glintborg, B , Østergaard, M, Krogh, N, Tarp, U, Loft, A, Hansen, A, Schlemmer, A, Fana, V, Kristensen, M, Lindegaard, HM, Nordin, H, Rasmussen, C, Ejstrup, L, Petersen, PM, Manilo, N, Jensen, DV & Hetland, ML 2012, 'Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondylitis switching anti tumor necrosis factor α therapy: Results from the Danish nationwide Danbio registry', Annals of the Rheumatic Diseases, vol. 71, no. Suppl. 3, pp. 111.

@article{d34dcbb9b45545bd8a014df8b1f7a8ab,

title = "Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondylitis switching anti tumor necrosis factor α therapy: Results from the Danish nationwide Danbio registry",

author = "Bente Glintborg and Mikkel {\O}stergaard and N. Krogh and U. Tarp and A. Loft and Annette Hansen and Annette Schlemmer and V. Fana and M. Kristensen and Lindegaard, \{Hanne Merete\} and H. Nordin and C. Rasmussen and L. Ejstrup and P.M. Petersen and N. Manilo and Jensen, \{Dorte Vendelbo\} and Hetland, \{Merete Lund\}",

year = "2012",

language = "English",

volume = "71",

pages = "111",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier BV",

number = "Suppl. 3",

}

TY - ABST

T1 - Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondylitis switching anti tumor necrosis factor α therapy: Results from the Danish nationwide Danbio registry

AU - Glintborg, Bente

AU - Østergaard, Mikkel

AU - Krogh, N.

AU - Tarp, U.

AU - Loft, A.

AU - Hansen, Annette

AU - Schlemmer, Annette

AU - Fana, V.

AU - Kristensen, M.

AU - Lindegaard, Hanne Merete

AU - Nordin, H.

AU - Rasmussen, C.

AU - Ejstrup, L.

AU - Petersen, P.M.

AU - Manilo, N.

AU - Jensen, Dorte Vendelbo

AU - Hetland, Merete Lund

PY - 2012

Y1 - 2012

M3 - Conference abstract in journal

SN - 0003-4967

VL - 71

SP - 111

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - Suppl. 3

ER -